Early Detection and Diagnosis

The best way to diagnose prostate cancer involves a digital rectal exam and a prostate specific antigen (PSA) blood test. Patients with localized cancer rarely have any symptoms. New markers for the early detection of prostate cancer are under development and study.

Digital Rectal Exam

The Digital Rectal Examination (DRE) may detect a cancer and judge whether it is confined to the prostate. The Prostate lies in front of the rectum; therefore, the doctor can feel the prostate by inserting a gloved, lubricated finger into the rectum. The DRE is not always accurate, as many prostate cancers are situated deeper in the gland or are too small for detection, and not all ‘lumps’ on the prostate are cancerous. Once a cancer can be felt as a lump, it is considered to be at a more advanced stage than when it is detected only by a PSA blood test.

Prostate-Specific Antigen (PSA)

Prostate-specific antigen (PSA) is a protein produced by both normal and cancerous prostate cells. When prostate cancer grows or when other prostate diseases are present, the amount of PSA in the blood may increase.

A PSA test is generally said to be in the normal range when it is reported to be between 0 and 2.5 nanograms per milliliter (sometimes abbreviated as ng/mL on the lab report) and not increasing over time. PSA may be elevated because of a non-cancerous condition, such as enlargement or inflammation of the prostate.

If the results are in the high range (or have increased since a prior test), your physician may suggest a biopsy, which is the only test to actually diagnose prostate cancer.

Click here to read the Vancouver Prostate Centre and BC Cancer Agency's recommendations on PSA screening (The Basics –> Screening for this Cancer)

Percent-Free PSA Ratio

Percent-free PSA ratio is a blood test that measures how much PSA circulates by itself (unbound) in the blood, and how much is bound together with other blood proteins. If PSA results are elevated and percent-free PSA ratio is low (10% or less), then prostate cancer is more likely to be present. If this is the case, a biopsy may be needed.

Ultrasound

Transrectal ultrasonography (TRUS) is the most direct way to see the prostate gland. Ultrasound provides an image that can be used to measure the size of the prostate and sometimes can detect suspicious tissue. TRUS is almost always done in combination with a biopsy. When a needle biopsy of the prostate is performed, it is always done under ultrasound guidance.

Biopsy

A prostate biopsy removes small amounts of tissue to examine under a microscope to determine whether cancer is present. Typically between 6 and 12 biopsies are taken from the prostate using a core biopsy needle. By examining tissue samples under a microscope, the diagnosis of cancer can be established. When a tumor is discovered, it is classified, under the microscope, into a category called tumor ‘grade’.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Plaid for Dad

Plaid for Dad Fundraiser, June 14, 2019

Plaid for Dad is a workplace fundraiser for Prostate Cancer Canada, with online registration & fundraising leading up to Friday June 14th's "wear plaid to work" day. Visit the event website to register a team, join/fundraise for a team or buy plaid to wear on the day.      

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC takes place on Sunday June 16, 2019 in various locations across BC. Registration fees ($40) include a shirt and BBQ lunch, and are waived for those who raise over $150. Click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Friday, May 3, 2019

Dr. Mads Daugaard receives the St. Baldrick’s Foundation Robert J. Arceci Innovation Award

Dr. Daugaard
Thursday, April 18, 2019

Dr. Subramaniam joins UBC as Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design

Dr. Subramaniam
Monday, April 1, 2019

VPC's translational research profiled in UBC Faculty of Medicine News

Dr. Gleave at the VPC